Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

作者：Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, Hans‐Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M. Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M. Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schüler, Wolf O. Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten Oliver Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel · 发表于：The Lancet Oncology · 年份：2016 · DOI：10.1016/s1470-2045(16)30531-9 · 被引用次数：751 · 研究领域：Esophageal Cancer Research and Treatment、Gastric Cancer Management and Outcomes、Gastrointestinal Tumor Research and Treatment